Fre­quen­cy fol­lows Astel­las pact with $62M round to bankroll PhII of lead re­gen­er­a­tive drug

A few days ago Fre­quen­cy Ther­a­peu­tics got some high pro­file en­dorse­ment on its small mol­e­cule strat­e­gy for re­gen­er­a­tive med­i­cine, when Astel­las of­fered $80 mil­lion up­front to part­ner on their lead drug. As it turns out, the Japan­ese phar­ma wasn’t the on­ly one in­trigued by the plat­form and up­com­ing Phase II study of FX-322.

Per­cep­tive Ad­vi­sors has jumped in to lead a $62 mil­lion Se­ries C, which al­so drew Deer­field Man­age­ment, RTW In­vest­ments and Mizuho Se­cu­ri­ties Prin­ci­pal In­vest­ment. Po­laris, Tai­wa­nia, Ax­il and Co­Bro al­so dou­bled down on their ex­ist­ing bet.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.